| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41591-019-0694-X |
| P698 | PubMed publication ID | 31873309 |
| P50 | author | Dana Pe'er | Q16204043 |
| Padmanee Sharma | Q63313365 | ||
| Amy B. Heimberger | Q88917854 | ||
| Thomas Walle | Q92229964 | ||
| P2093 | author name string | Hao Zhao | |
| James P Allison | |||
| John de Groot | |||
| Scott Kopetz | |||
| Sangeeta Goswami | |||
| Michael Overman | |||
| Luis Vence | |||
| Boris Sepesi | |||
| Jorge Blando | |||
| Irina Fernandez | |||
| Martina Ott | |||
| Sreyashi Basu | |||
| Swetha Anandhan | |||
| Andrew E Cornish | |||
| Shalini Singh Yadav | |||
| Ling Y Kong | |||
| P2860 | cites work | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| The future of immune checkpoint therapy | Q28259862 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Normalization of mass cytometry data with bead standards | Q30604177 | ||
| viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia | Q30628090 | ||
| Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach | Q92584037 | ||
| CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling | Q92707925 | ||
| Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39 | Q92955884 | ||
| FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data | Q30883687 | ||
| Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis | Q30975629 | ||
| An Immune Atlas of Clear Cell Renal Cell Carcinoma | Q33649707 | ||
| Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy | Q33912938 | ||
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 | ||
| CSF-1R inhibition alters macrophage polarization and blocks glioma progression | Q34993852 | ||
| Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm | Q35141765 | ||
| Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial | Q35567212 | ||
| CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5 | Q35911313 | ||
| MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints | Q36785139 | ||
| CD39 and CD73 in immunity and inflammation | Q36906658 | ||
| Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis | Q38253037 | ||
| Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential | Q38414485 | ||
| Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. | Q38695379 | ||
| Hypoxia and macrophages promote glioblastoma invasion by the CCL4-CCR5 axis | Q38740687 | ||
| Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy | Q38743794 | ||
| Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial | Q39107888 | ||
| LAG3 (CD223) as a cancer immunotherapy target | Q39160974 | ||
| Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies | Q39414029 | ||
| CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis | Q39598074 | ||
| CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells | Q40619963 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors | Q46182062 | ||
| Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. | Q47141786 | ||
| Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade | Q47958949 | ||
| Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma | Q48293592 | ||
| Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. | Q50647447 | ||
| Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. | Q50858761 | ||
| Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. | Q52644831 | ||
| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma | Q62745893 | ||
| Recovering Gene Interactions from Single-Cell Data Using Data Diffusion | Q89367601 | ||
| Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment | Q89367617 | ||
| CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth | Q90995209 | ||
| Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer | Q91385882 | ||
| Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma | Q91451450 | ||
| Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies | Q92217622 | ||
| P433 | issue | 1 | |
| P921 | main subject | glioblastoma | Q282142 |
| P304 | page(s) | 39-46 | |
| P577 | publication date | 2019-12-23 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma | |
| P478 | volume | 26 |
| Q92564956 | Dissecting the mechanisms of immune checkpoint therapy |
| Q98465720 | Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade |
| Q101149107 | Progress and applications of mass cytometry in sketching immune landscapes |
| Q91712001 | Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors |
| Q96126940 | Toward personalized synchrotron microbeam radiation therapy |
| Q98466291 | Unraveling the Complexity of the Cancer Microenvironment With Multidimensional Genomic and Cytometric Technologies |
Search more.